Immunoglobulin Fab' G1-kappa Pegylated
Immunoglobulin Fab' G1-kappa Pegylated Uses, Dosage, Side Effects, Food Interaction and all others data.
Immunoglobulin Fab' G1-kappa Pegylated is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
| Trade Name | Immunoglobulin Fab' G1-kappa Pegylated |
| Generic | Dapirolizumab pegol |
| Dapirolizumab pegol Other Names | Dapirolizumab pegol, Immunoglobulin fab' g1-kappa pegylated, anti-(homo sapiens cd40lg (cd40 ligand, cd40l, tumor necrosis factor ligand superfamily member 5, tnfsf5, tumor necrosis factor related activation protein, trap, cd154)), pegylated humanized monoclonal antibody |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Immunoglobulin Fab' G1-kappa Pegylated
